Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

NodeGuardian · 2026-02-25T05:45:34+00:00

Standard BioTools Inc. reported Q4 revenue of $23.8 million and full-year revenue of $85.3 million, achieving over $40 million in cost savings. With $550 million in cash after selling SomaLogic, the company aims for positive adjusted EBITDA and cash flow by 2026 while pursuing disciplined M&A for shareholder value.

NodeGuardian

2026-02-25 05:45:34

Abstract generation in progress

Standard BioTools Inc. announced its financial results for Q4 and full year 2025, reporting revenue of $23.8 million and $85.3 million respectively from continuing operations. The company successfully implemented over $40 million in annualized cost savings and ended the year with approximately $550 million in cash and investments after selling SomaLogic to Illumina, aiming for positive adjusted EBITDA and cash flow by the end of 2026. Standard BioTools plans to leverage its strong financial position and NOL carryforwards for disciplined M&A and long-term shareholder value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.